BioNTech mRNA Cancer Vaccine Fails Phase 3 Trial, Shaking Oncology Confidence

BioNTech's mRNA-based cancer vaccine candidate failed its Phase 3 clinical trial, dealing a significant blow to analyst confidence in the technology's near-term oncology prospects. The failure adds to divergent results across the field, prompting researchers to reassess the promise of mRNA platforms for cancer treatment beyond infectious disease applications. The setback highlights the gap between early-phase enthusiasm and late-stage clinical performance in oncology.